LITS Stock — Lite Strategy Inc.: Cash, EV, Pipeline

Share price

$1.13

Market cap

$36.0M

Cash

$7.5M

Enterprise value

$28.5M

Balance sheet

Cash	$7.5M
Debt	$0.0M
Net cash	$7.5M
Enterprise value	$28.5M
Basic shares	35.2M shares
Fully diluted shares	38.8M shares
Fully diluted market cap	$43.9M
Cash per share	$0.21

Cash figures as of 2026-03-31. Database snapshot: 2026-09-21.

Price history

Loading LITS daily closes…

Loading price history…

Pipeline assets

Voruciclib

Preclinical · Active Modality: oral selective CDK9 inhibitor

Target CDK9

Partnerships Presage (exclusive worldwide license)

Indications

non-oncology indications (preclinical) (Preclinical)

Status note All oncology clinical development discontinued; clinical trial activities ceased September 2024; preclinical work in non-oncology indications commenced Q2 FY2026.

Zandelisib

Phase 2 · Terminated Modality: oral selective PI3K-delta inhibitor

Target PI3K-delta

Partnerships Kyowa Kirin (license terminated 2023)

Indications

indolent B-cell lymphomas (Phase 2)

Status note Development discontinued November 2022 after FDA feedback on Phase 3 COASTAL design; assessing out-licensing or sale opportunities.

Per-asset detail extracted from the 10-Q filed 2026-05-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	67,292	no change	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

LITS — Lite Strategy Inc.

Balance sheet

Price history

Pipeline assets

Institutional holders